Levomilnacipran: Side Effects, Uses & Monitoring

Facts extracted from current FDA product labeling for Levomilnacipran. Educational only — not medical advice.

Labeled uses

FETZIMA® is indicated for the treatment of major depressive disorder (MDD) in adults [see Clinical Studies ( 14 )]. Limitation of Use: FETZIMA is not approved for the management of fibromyalgia. The efficacy and safety of FETZIMA for the management of fibromyalgia have not been established.

Source: FDA labeling via NIH DailyMed (set f371258d…). Not affiliated with FDA or NIH.

Medical disclaimer: Always consult a qualified healthcare professional about any medication.

Ratings summarize government-reported measures — they don't capture your personal needs. Visit the facility, ask about staffing and services, and use CMS checklists. This profile is informational only and is not a recommendation.